Related Experiment Videos
[Cystic fibrosis and bronchial hyper-reactivity]
M Oswald-Mammosser1, L Donato, A Vandevenne
1Service de Pneumologie, Hôpital de Hautepierre, Strasbourg.
Revue Des Maladies Respiratoires
|January 1, 1991
Summary
Bronchodilators may help cystic fibrosis (CF) patients with airway hyperreactivity, but their effectiveness varies. Careful patient monitoring and pulmonary function tests are essential for personalized CF treatment.
Area of Science:
- Pulmonary Medicine
- Respiratory Physiology
Context:
- Cystic Fibrosis (CF) patients often exhibit increased airway responsiveness to stimuli.
- Bronchial hyperreactivity in CF is frequently linked to mucosal damage, not solely asthma.
- The utility of bronchodilators in CF remains a subject of debate.
Purpose:
- To investigate the role and efficacy of bronchodilators in managing airway hyperreactivity in cystic fibrosis.
- To explore the variability in patient response to bronchodilator therapy.
Summary:
- Airway hyperresponsiveness is common in cystic fibrosis, often due to bronchial mucosal damage.
- Adverse effects from beta-mimetic drugs have been reported, possibly due to bronchial wall instability.
- Evidence suggests bronchodilators can be beneficial in specific CF cases and disease stages.
- Therapeutic response to bronchodilators is highly variable among CF patients, necessitating individualized treatment approaches.
Impact:
- Highlights the need for personalized bronchodilator therapy in cystic fibrosis management.
- Emphasizes the importance of pulmonary function testing before and during bronchodilator use in CF patients.
- Informs clinical practice regarding the cautious and tailored application of bronchodilators for airway hyperreactivity in cystic fibrosis.